Influence of Body Composition on Chemotherapy Outcomes in Localized Breast Cancer

The purpose of this study is to determine if pharmacokinetics of docetaxel is modified by the body composition (assessed by the BMI but also by CT-scan) in patients treated by docetaxel as adjuvant treatment of a localized breast cancer

Trial Details

NCT ID
NCT05858398
Phase
NA
Sponsor
Centre Henri Becquerel
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • pharmacokinetics blood sample assessment
Locations (sample)
  • Rouen, France|49.44313,1.09932

Key Eligibility Criteria

  • Woman older than
  • Early breast cancer
  • CT-scan of less than 3 months, including L3 level
  • Indication of docetaxel at 100 mg/m² as adjuvant CT

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →